This phase III trial is evaluating the safety and effectiveness of using a combination of a targeted therapy (Pembrolizumab) and an anti-hormonal therapy (Enzalutamide) to treat patients with metastatic castration-resistant prostate cancer..
This trial is treating patients with metastatic castration-resistant prostate cancer (mCRPC).
This is a systemic therapy.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Study of Pembrolizumab (MK-3475) plus Enalutamide versus placebo plus Enzalutamide in participants with metastatic castraion-resistant prostate cancer (mCRPC)
Eligible participants will receive either intravenous infusions of pembrolizumab or placebo on Day 1 of each 28-day cycle for up to 35 cycles, in addition to single daily orally administered doses of Enzalutamide.
Recruiting Hospitals Read More